Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma

Date

21 Oct 2023

Session

Poster session 18

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Young Mi Hong

Citation

Annals of Oncology (2023) 34 (suppl_2): S594-S618. 10.1016/S0923-7534(23)01939-7

Authors

K.T. Yoon1, H. Ryu2, T.U. Kim2

Author affiliations

  • 1 Internal Medicine, Pusan National University Yangsan Hospital, 626-770 - Yangsan/KR
  • 2 Radiology, Pusan National University Yangsan Hospital, 626-770 - Yangsan/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 980P

Background

Systemic inflammatory markers have emerged as novel prognostic biomarkers associated with prognosis for tumors. This study aims to investigate the predictive value of systemic inflammatory markers for complete response (CR) in patients with hepatocellular carcinoma (HCC) who undergo transarterial chemoembolization (TACE).

Methods

This retrospective study enrolled 575 treatment-naïve patients with HCC who underwent TACE. Survival outcomes were evaluated based on tumor response, and the analysis was conducted using a Kaplan-Meier curve. Predictive factors for achieving a CR after the initial TACE were analyzed by univariate and multivariate analysis in a Cox regression model.

Results

After the initial TACE, 246 of 575 (37.0%) patients achieved CR. During a median of 60 months follow-up, CR group had better overall survival than non-CR group (median: 82.3 vs. 51.6 months, P<0.001). Pre-TACE neutrophil count was associated with tumor response (P=0.06). Multivariate analysis showed that hepatitis B virus infection (hazard ratio [HR]=0.585, 95% CI=0.360-0.952, P =0.031) and pre-TACE neutrophil count (HR=2.854, 95% CI=1.115-7.307, P=0.029) were independent predictive factors for CR after the initial TACE. Additionally, high pre-TACE neutrophil count was associated with male gender (P<0.001), large tumor size (P<0.001), advanced Barcelona Clinic Liver Cancer stage (P=0.003) and high PIVKA-II level (P<0.001).

Conclusions

Patients who achieved CR after the initial TACE showed a favorable prognosis. Pre-TACE neutrophil count was found to be an independent predictor of CR. These findings offer valuable insights for identifying patients who would derive the greatest benefit from TACE and for distinguishing those who may require alternative treatment approaches for HCC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.